Matches in SemOpenAlex for { <https://semopenalex.org/work/W2288504117> ?p ?o ?g. }
- W2288504117 endingPage "e0149919" @default.
- W2288504117 startingPage "e0149919" @default.
- W2288504117 abstract "The most relevant therapeutic approaches to treat CML rely on the administration of tyrosine kinase inhibitors (TKIs) like Imatinib, which are able to counteract the activity of Bcr-Abl protein increasing patient's life expectancy and survival. Unfortunately, there are some issues TKIs are not able to address; first of all TKIs are not so effective in increasing survival of patients in blast crisis, second they are not able to eradicate leukemic stem cells (LSC) which represent the major cause of disease relapse, and third patients often develop resistance to TKIs due to mutations in the drug binding site. For all these reasons it's of primary interest to find alternative strategies to treat CML. Literature shows that Hedgehog signaling pathway is involved in LSC maintenance, and pharmacological inhibition of Smoothened (SMO), one of the key molecules of the pathway, has been demonstrated to reduce Bcr-Abl positive bone marrow cells and LSC. Consequently, targeting SMO could be a promising way to develop a new treatment strategy for CML overcoming the limitations of current therapies. In our work we have tested some compounds able to inhibit SMO, and among them MRT92 appears to be a very potent SMO antagonist. We found that almost all our compounds were able to reduce Gli1 protein levels in K-562 and in KU-812 CML cell lines. Furthermore, they were also able to increase Gli1 and SMO RNA levels, and to reduce cell proliferation and induce apoptosis/autophagy in both the tested cell lines. Finally, we demonstrated that our compounds were able to modulate the expression of some miRNAs related to Hedgehog pathway such as miR-324-5p and miR-326. Being Hedgehog pathway deeply implicated in the mechanisms of CML we may conclude that it could be a good therapeutic target for CML and our compounds seem to be promising antagonists of such pathway." @default.
- W2288504117 created "2016-06-24" @default.
- W2288504117 creator A5005793362 @default.
- W2288504117 creator A5030796321 @default.
- W2288504117 creator A5032250855 @default.
- W2288504117 creator A5051860861 @default.
- W2288504117 creator A5055343453 @default.
- W2288504117 creator A5076377697 @default.
- W2288504117 creator A5077488322 @default.
- W2288504117 date "2016-03-02" @default.
- W2288504117 modified "2023-09-30" @default.
- W2288504117 title "Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells" @default.
- W2288504117 cites W1490418776 @default.
- W2288504117 cites W1490860457 @default.
- W2288504117 cites W1503481430 @default.
- W2288504117 cites W1982401508 @default.
- W2288504117 cites W1983031752 @default.
- W2288504117 cites W1984214021 @default.
- W2288504117 cites W1997905438 @default.
- W2288504117 cites W1998593414 @default.
- W2288504117 cites W2003973314 @default.
- W2288504117 cites W2014017623 @default.
- W2288504117 cites W2016086822 @default.
- W2288504117 cites W2027904894 @default.
- W2288504117 cites W2030195553 @default.
- W2288504117 cites W2041004587 @default.
- W2288504117 cites W2041440798 @default.
- W2288504117 cites W2055049504 @default.
- W2288504117 cites W2057375535 @default.
- W2288504117 cites W2058174450 @default.
- W2288504117 cites W2064068640 @default.
- W2288504117 cites W2069444276 @default.
- W2288504117 cites W2071645102 @default.
- W2288504117 cites W2077972066 @default.
- W2288504117 cites W2083945212 @default.
- W2288504117 cites W2085110097 @default.
- W2288504117 cites W2089483984 @default.
- W2288504117 cites W2099118069 @default.
- W2288504117 cites W2099663271 @default.
- W2288504117 cites W2100303227 @default.
- W2288504117 cites W2107503279 @default.
- W2288504117 cites W2110648386 @default.
- W2288504117 cites W2111197864 @default.
- W2288504117 cites W2112817157 @default.
- W2288504117 cites W2118081225 @default.
- W2288504117 cites W2123600514 @default.
- W2288504117 cites W2124105006 @default.
- W2288504117 cites W2124196948 @default.
- W2288504117 cites W2127292866 @default.
- W2288504117 cites W2128175263 @default.
- W2288504117 cites W2128775062 @default.
- W2288504117 cites W2132749637 @default.
- W2288504117 cites W2140350596 @default.
- W2288504117 cites W2141078839 @default.
- W2288504117 cites W2151907359 @default.
- W2288504117 cites W2158884958 @default.
- W2288504117 cites W2159970646 @default.
- W2288504117 cites W2160851769 @default.
- W2288504117 cites W2160889747 @default.
- W2288504117 cites W2162098634 @default.
- W2288504117 cites W2168373302 @default.
- W2288504117 cites W2313598718 @default.
- W2288504117 cites W2317901346 @default.
- W2288504117 cites W2738996050 @default.
- W2288504117 cites W4232256978 @default.
- W2288504117 doi "https://doi.org/10.1371/journal.pone.0149919" @default.
- W2288504117 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4774938" @default.
- W2288504117 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26934052" @default.
- W2288504117 hasPublicationYear "2016" @default.
- W2288504117 type Work @default.
- W2288504117 sameAs 2288504117 @default.
- W2288504117 citedByCount "8" @default.
- W2288504117 countsByYear W22885041172018 @default.
- W2288504117 countsByYear W22885041172019 @default.
- W2288504117 countsByYear W22885041172021 @default.
- W2288504117 countsByYear W22885041172022 @default.
- W2288504117 countsByYear W22885041172023 @default.
- W2288504117 crossrefType "journal-article" @default.
- W2288504117 hasAuthorship W2288504117A5005793362 @default.
- W2288504117 hasAuthorship W2288504117A5030796321 @default.
- W2288504117 hasAuthorship W2288504117A5032250855 @default.
- W2288504117 hasAuthorship W2288504117A5051860861 @default.
- W2288504117 hasAuthorship W2288504117A5055343453 @default.
- W2288504117 hasAuthorship W2288504117A5076377697 @default.
- W2288504117 hasAuthorship W2288504117A5077488322 @default.
- W2288504117 hasBestOaLocation W22885041171 @default.
- W2288504117 hasConcept C145837895 @default.
- W2288504117 hasConcept C203014093 @default.
- W2288504117 hasConcept C2777413986 @default.
- W2288504117 hasConcept C2777583451 @default.
- W2288504117 hasConcept C2778461978 @default.
- W2288504117 hasConcept C2778729363 @default.
- W2288504117 hasConcept C2779933373 @default.
- W2288504117 hasConcept C2780381907 @default.
- W2288504117 hasConcept C28328180 @default.
- W2288504117 hasConcept C3019892230 @default.
- W2288504117 hasConcept C42362537 @default.
- W2288504117 hasConcept C502942594 @default.